Global Hepatocellular Carcinoma Drugs Market – Industry Trends and Forecast to 2030

Pedido de resumo Pedido de TOC Fale com Analista Fale com o analista  Comprar agora Comprar agora Consulte antes Comprar Consulte antes Relatório de amostra grátis Relatório de amostra grátis

Global Hepatocellular Carcinoma Drugs Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Reports
  • Dec 2022
  • Global
  • 350 Páginas
  • Número de tabelas: 220
  • Número de figuras: 60

Global Hepatocellular Carcinoma Drugs Market

Tamanho do mercado em biliões de dólares

CAGR :  % Diagram

Chart Image USD 1.04 Billion USD 1.95 Billion 2022 2030
Diagram Período de previsão
2023 –2030
Diagram Tamanho do mercado (ano base )
USD 1.04 Billion
Diagram Tamanho do mercado ( Ano de previsão)
USD 1.95 Billion
Diagram CAGR
%
Diagram Principais participantes do mercado
  • Manequim1
  • Manequim2
  • Manequim3
  • Manequim4
  • Manequim5

>Global Hepatocellular Carcinoma Drugs Market, By Drug Class, (PD-1/PD-L1 Inhibitors, and Tyrosine Kinase Inhibitors), Therapy Type (Targeted Therapy, Immunotherapy, Others), Treatment Type (Medication, Surgery, Radiotherapy, Chemotherapy, Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

Hepatocellular Carcinoma Drugs Market

Hepatocellular Carcinoma Drugs Market Analysis and Size

The incidence of HCC has evolved considerably during the past few decades and it has become the third leading cause of deaths by cancer globally. The incidence of hepatitis B and hepatitis C chronic liver diseases are growing, the incidence of HCC is prevalent in Asia and Africa, with prevalence rates in men of 35 per 100,000 populations.

Data Bridge Market Research analyses a growth rate in the hepatocellular carcinoma drugs market in the forecast period 2023-2030. The expected CAGR of hepatocellular carcinoma drugs market is tend to be around 8.2% in the mentioned forecast period. The market was valued at USD 1.04 billion in 2022, and it would grow up to USD 1.95 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Hepatocellular Carcinoma Drugs Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Drug Class, (PD-1/PD-L1 Inhibitors, and Tyrosine Kinase Inhibitors), Therapy Type (Targeted Therapy, Immunotherapy, Others), Treatment Type (Medication, Surgery, Radiotherapy, Chemotherapy, Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Exelixis, Inc (U.S.), Merck & Co., Inc.(U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), Lilly (U.S.), SillaJen, Inc (South Korea), Bayer AG (Germany), Janssen Global Services, LLC (U.S.), Pfizer Inc (U.S.), CELGENE CORPORATION (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Gilead Sciences, Inc (U.S.), GSK plc (U.K.), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd (Japan), Amgen Inc. (U.S.), Polaris Group (U.S.), Hepion Pharmaceuticals (U.S.), PROVECTUS BIOPHARMACEUTICALS, INC (U.S.)

Market Opportunities

  • Increasing Strategic Collaborations Between Organizations
  • Increasing Prevalence of Hepatocellular Carcinoma

Market Definition

Hepatocellular carcinoma (HCC) is a major kind of primary liver cancer which arises from the liver cells or hepatocytes. The disease is more prevalent in patients with hepatitis B, hepatitis C, cirrhosis, obesity, and diabetes. Diagnosis of this condition is largely done by several imaging tests such as ultrasound, CT scan, MRI, and liver biopsy. Treatment includes ablation therapy in addition to chemotherapy, radiation therapy, and targeted drug therapy. Mjority of HCC is witnessed in patients with end-stage liver dysfunction.  

Hepatocellular Carcinoma Drugs Market Dynamics

Drivers

  • Increased Prevalence of Liver Cancer

According to the survey by the Health Science Department, University of California, Los Angeles, (UCLA), 2017, hepatocellular carcinoma (HCC) accounts for three quarters of liver cancers in the U.S. with almost 40,000 Americans diagnosed with liver cancer in 2017 and above 28,000 deaths are reported from the disease. Furthermore, in April 2018, Eli Lilly and Company completed Phase 3 research study of Cyramza as a single agent in the second-line treatment of people suffering from hepatocellular carcinoma.

  • Rising Approval of Novel Drugs

There are several clinical advancements combined with the approval of novel drugs by the regulatory agencies for the treatment of hepatocellular carcinoma is enhancing growth of the market. For instance, in April 2017, the U.S. FDA expanded the indications of regorafenib manufactured by Bayer HealthCare Pharmaceuticals Inc., for treatment of patients suffering from hepatocellular carcinoma. The therapy showed major improvement in survival for patients after the failure of standard treatments. Furthermore, in 2017, the U.S. FDA granted accelerated approval for nivolumab (Opdivo) drug developed by Bristol-Myers Squibb for treating hepatocellular carcinoma.

Opportunities

  • Increasing Strategic Collaborations Between Organizations

The manufactures are focused on several strategic collaborations to jointly develop and commercialize immunotherapies that are indicated to treat wide range of tumors. For instance, in 2014, Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd. made a strategic collaboration agreement to jointly develop and commercialize several immunotherapies as single and combination therapies with Opdivo, to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan. Additionally, in 2015, Novartis Pharmaceuticals initiated the Phase 2 trials to compare the safety and efficacy for dovitinib and sorafenib in adult patients for treating advanced hepatocellular carcinoma.

  • Increasing Prevalence of Hepatocellular Carcinoma

According to the latest research by International Journal of Cancer Research and Treatment, 2014, HCC is the sixth most common type of cancer worldwide and third most common cause of death worldwide, fifth for men and eighth for women. The disease accounts for more than 5% of all cancers and for 80-90% of primary liver cancers. Furthermore, as per the Addis Ababa University, 2017, hepatocellular carcinoma (HCC) resulted in around 854,000 new cases of liver cancer and 810,000 related deaths in 2015

 Restraints/Challenges

  • Lack of Drug Approvals

The extreme lack of drug approvals by authorized organizations is hampering the market growth. There are no FDA-approved drugs to treat HCC. Additionally, the limited availability of treatment processes can limit market growth.

  • High Cost of Treatment

The rising expenditure associated with the various medications impede the market growth. Additionally, several diagnostic procedures including imaging procedures and liver tissue examination hamper the market's growth.

This hepatocellular carcinoma drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hepatocellular carcinoma drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Hepatocellular Carcinoma Drugs Market Scope

The hepatocellular carcinoma drugs market is segmented on the basis of drug class, treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

  • PD-1/PD-L1 Inhibitors
  • Atezolizumab (Tecentriq)
  • Avelumab (Bavencio)
  • Durvalumab (Imfinzi)
  • Tyrosine Kinase Inhibitors
  • Gefitinib
  • Erlotinib
  • Sorafenib
  • Treatment

Treatment Type

  • Medication
  • Surgery
  • Radiotherapy
  • Chemotherapy
  • Others

Route of Administration

  • Oral
  • Injectable
  • Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Hepatocellular Carcinoma Drugs Market Regional Analysis/Insights

The hepatocellular carcinoma drugs market is analyzed and market size insights and trends are provided by drug class, treatment type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the hepatocellular carcinoma drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has witnessed the highest growth for hepatocellular carcinoma drugs market throughout the forecasted period due to the developing number of R&D activities attempted by the companies in the region to create effective treatments for treating of hepatocellular carcinoma.

North America dominates the market due to the presence of key manufacturers of the product and treatment processes.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Hepatocellular Carcinoma Drugs Market Share Analysis

The hepatocellular carcinoma drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hepatocellular carcinoma drugs market.

Key players operating in the hepatocellular carcinoma drugs market include:

  • Exelixis, Inc (U.S.)
  • Merck & Co., Inc.(U.S.)
  • AstraZeneca (U.K.)
  • Bristol-Myers Squibb Company (U.S.)
  • Lilly (U.S.)
  • SillaJen, Inc (South Korea)
  • Bayer AG (Germany)
  • Janssen Global Services, LLC (U.S.)
  • Pfizer Inc (U.S.)
  • CELGENE CORPORATION (U.S.)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Gilead Sciences, Inc (U.S.)
  • GSK plc (U.K.)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Eisai Co., Ltd (Japan)
  • Amgen Inc. (U.S.)
  • Polaris Group (U.S.)
  • Hepion Pharmaceuticals (U.S.)
  • PROVECTUS BIOPHARMACEUTICALS, INC (U.S.)

SKU-

Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo

  • Painel interativo de análise de dados
  • Painel de análise da empresa para oportunidades de elevado potencial de crescimento
  • Acesso de analista de pesquisa para personalização e customização. consultas
  • Análise da concorrência com painel interativo
  • Últimas notícias, atualizações e atualizações Análise de tendências
  • Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Pedido de demonstração

Metodologia de Investigação

A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados ​​e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.

A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis ​​de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.

Personalização disponível

A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.

Perguntas frequentes

O mercado é segmentado com base em , By Drug Class, (PD-1/PD-L1 Inhibitors, and Tyrosine Kinase Inhibitors), Therapy Type (Targeted Therapy, Immunotherapy, Others), Treatment Type (Medication, Surgery, Radiotherapy, Chemotherapy, Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030. .
O tamanho do Global Hepatocellular Carcinoma Drugs Market foi avaliado em USD 1.04 USD Billion no ano de 2022.
O Global Hepatocellular Carcinoma Drugs Market está projetado para crescer a um CAGR de 8.2% durante o período de previsão de 2023 a 2030.
O relatório de mercado cobre dados de U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Testimonial